Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: The example of losartan

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Jiang, Peng ^a,b   Loyau, Stéphane ^a   Tchitchinadze, Maria ^c   Ropers, Jacques ^d   Jondeau, Guillaume ^a,b,c   Jandrot Perrus, Martine ^a,b  

^a Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) [1,1' BIPHENYL] 4 YL]METHYL] 1H IMIDAZOLE 5 CARBOXALDEHYDE; COLLAGEN; GLYCOPROTEIN VI; LOSARTAN; PADGEM PROTEIN; PLACEBO; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR; IMMOBILIZED PROTEIN; PEPTIDE; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN BINDING; THROMBIN RECEPTOR;

ANTIPLATELET ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CELL INTERACTION; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; EX VIVO STUDY; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MAJOR CLINICAL STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; ANIMAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; FLOW KINETICS; HORSE; MARFAN SYNDROME; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; THROMBOCYTE; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELETS; COLLAGEN; HORSES; HUMANS; IMMOBILIZED PROTEINS; INTEGRIN ALPHA2BETA1; LOSARTAN; MARFAN SYNDROME; PEPTIDES; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, THROMBIN; RHEOLOGY; THROMBOSIS;

EID: 84936797745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128744     Document Type: Article

References (49)

1. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003; 102 (2):449-61. PMID: 12649139
2. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998; 94(5):657-66. PMID: 9741630
3. Loyau S, Dumont B, Ollivier V, Boulaftali Y, Feldman L, Ajzenberg N, et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol. 2012; 32(3):778-85. doi: 10.1161/ATVBAHA.111.241067 PMID: 22155453
4. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem. 1999; 274(41):29019-24. PMID: 10506151
5. Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong XM, Debili N, Chickering T, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood. 2000; 96(5):1798-807. PMID: 10961879
6. Suzuki-Inoue K, Tulasne D, Shen Y, Bori-Sanz T, Inoue O, Jung SM, et al. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem. 2002; 277 (24):21561-6. PMID: 11943772
7. Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, et al. Human platelet glycoprotein VI function is antagonized by monoclonal anti body-derived Fab fragments. J Thromb Haemost. 2003; 1 (12):2653-62. PMID: 14675102
8. Bultmann A, Herdeg C, Li Z, Munch G, Baumgartner C, Langer H, et al. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Thromb Haemost. 2006; 95 (5):763-6. PMID: 16676064
9. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989; 84(5):1440-5. PMID: 2808700
10. Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol. 1995; 89(1):124-30. PMID: 7530476
11. Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res. 2006; 118(3):371-80. PMID: 16139873
12. Bigalke B, Kramer BF, Seizer P, Fateh-Moghadam S, Gawaz M, Lindemann S. Diagnostic and therapeutic potentials of platelet glycoprotein VI. Semin Thromb Hemost. 2010; 36(2):203-11. doi: 10.1055/ s-0030-1251505 PMID: 20414836
13. Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins. 1992; 44(2):89-99. PMID: 1438880
14. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998; 32(2):198-205. PMID: 9700980
15. Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W. Losartan inhibits the adhesion of rat platelets to fibrillar collagen - a potential role of nitric oxide and prostanoids. J Physiol Pharmacol. 2000; 51 (4 Pt 1):705-13. PMID: 11192943
16. Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, et al. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol. 2007; 27(5):1184-90. PMID: 17347483
17. Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, Shimada I, et al. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem. 2010; 53(5):2087-93. doi: 10.1021/jm901534d PMID: 20158191
18. Taylor L, Vasudevan SR, Jones CI, Gibbins JM, Churchill GC, Campbell RD, et al. Discovery of novel GPVI receptor antagonists by structure-based repurposing. PLoS ONE. 2014; 9(6):e101209. doi: 10. 1371/journal.pone.0101209 PMID: 24971515
19. Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the interaction of platelet collagen receptor glyco-protein VI (GPVI)with collagen - A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem. 2002; 277(48):46197-204. PMID: 12356768
20. Dumont B, Minullina I, Loyau S, Monteiro RC, Lacapere JJ, Arocas V, et al. Chimeric Fc receptors identify ligand binding regions in human glycoprotein VI. J Mol Biol. 2006; 361(5):877-87. PMID: 16876821
21. Lecut C, Arocas V, Ulrichts H, Elbaz A, Villeval JL, Lacapere JJ, et al. Identification of residues within human glycoprotein VI involved in the binding to collagen - Evidence for the existence of distinct binding sites. J Biol Chem. 2004; 279(50):52293-9. PMID: 15466473
22. Lagrue-Lak-Hal AH, Debili N, Kingbury G, Lecut C, Le Couedic JP, Villeval JL, et al. Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J Biol Chem. 2001; 276 (18):15316-25. PMID: 11278467
23. Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha2beta1. J Biol Chem. 1997; 272(43):27035-41. PMID: 9341142
24. Zahid M, Loyau S, Bouabdelli M, Aubrey N, Jandrot-Perrus M, Billiald P. Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential. Anal Biochem. 2011; 417(2):274-82. doi: 10.1016/j.ab.2011.06.036 PMID: 21771576
25. Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Archives of cardiovascular diseases. 2010; 103(5):317-25. doi: 10. 1016/j.acvd.2010.04.008 PMID: 20619242
26. Tamaki T, Nishiyama A, Kimura S, Aki Y, Yoshizumi M, Houchi H, et al. EXP3174: The Major Active Metabolite of Losartan. Cardiovasc Drug Rev. 1997; 15(2):122-36.
27. Onley DJ, Knight CG, Tuckwell DS, Barnes MJ, Farndale RW. Micromolar Ca2+ concentrations are essential for Mg2+-dependent binding of collagen by the integrin alpha 2beta 1 in human platelets. J Biol Chem. 2000; 275(32):24560-4. PMID: 10827198
28. Knight CG, Morton LF, Peachey AR, Tuckwell DS, Farndale RW, Barnes MJ. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J Biol Chem. 2000; 275(1):35-40. PMID: 10617582
29. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, et al. Glycoprotein VI is a major collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood. 1998; 91(2):491-9. PMID: 9427702
30. Jung SM, Moroi M, Soejima K, Nakagaki T, Miura Y, Berndt MC, et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem. 2012; 287(35):30000-13. doi: 10.1074/jbc.M112.359125 PMID: 22773837
31. Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood. 2006; 108(3):936-42. PMID: 16861347
32. Sigalov AB. Novel mechanistic concept of platelet inhibition. Expert Opin Ther Targets. 2008; 12 (6):677-92. doi: 10.1517/14728222.12.6.677 PMID: 18479215
33. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002; 40(4):521-7. PMID: 12364357
34. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens. 2000; 14(9):581-5. PMID: 10980590
35. Senchenkova EY, Russell J, Almeida-Paula LD, Harding JW, Granger DN. Angiotensin II-mediated microvascular thrombosis. Hypertension. 2010; 56(6):1089-95. doi: 10.1161/HYPERTENSIONAHA.110. 158220 PMID: 20975035
36. Nieswandt B, Bergmeier WG, Eckly A, Schulte V, Ohlmann P, Cazenave JP, et al. Evidence for crosstalk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. Blood. 2001; 97(12):3829-35. PMID: 11389023
37. Tole S, Durkan AM, Huang YW, Liu GY, Leung A, Jones LL, et al. Thromboxane prostanoid receptor stimulation induces shedding of the transmembrane chemokine CX3CL1 yet enhances CX3CL1-dependent leukocyte adhesion. Am J Physiol Cell Physiol. 2010; 298(6):C1469-80. doi: 10.1152/ajpcell. 00380.2009 PMID: 20237149
38. Zervou M, Cournia Z, Potamitis C, Patargias G, Durdagi S, Grdadolnik SG, et al. Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach. Biochim Biophys Acta. 2014; 1838(3):1031-46. doi: 10.1016/j.bbamem.2013.12. 012 PMID: 24374319
39. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992; 51(5):513-21. PMID: 1587065
40. Murad JP, Espinosa EV, Ting HJ, Khasawneh FT. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther. 2012; 17(3):308-14. doi: 10.1177/ 1074248411425491 PMID: 22123197
41. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312(5770):117-21. PMID: 16601194
42. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aorticroot dilation in Marfan's syndrome. N Engl J Med. 2008; 358(26):2787-95. doi: 10.1056/ NEJMoa0706585 PMID: 18579813
43. Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol. 2013; 112(9):1477-83. doi: 10.1016/j.amjcard.2013.06.019 PMID: 23871676
44. Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2008; 31(9):1711-7. doi: 10.1291/hypres.31.1711 PMID: 18971549
45. Presta P, Minutolo R, Iodice C, Comi N, Casoria V, Fuiano L, et al. Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. European journal of internal medicine. 2011; 22(6):e90-4. doi: 10.1016/j.ejim.2011.08.021 PMID: 22075320
46. Geirsson A, Singh M, Ali R, Abbas H, Li W, Sanchez JA, et al. Modulation of transforming growth factor-beta signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation. 2012; 126(11 Suppl 1):S189-97. PMID: 22965982
47. Touat Z, Lepage L, Ollivier V, Nataf P, Hvass U, Labreuche J, et al. Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm. Arterioscler Thromb Vasc Biol. 2008; 28(5):940-6. doi: 10.1161/ATVBAHA.107.158576 PMID: 18292393
48. Devi S, Kuligowski MP, Kwan RY, Westein E, Jackson SP, Kitching AR, et al. Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway. Am J Pathol. 2010; 177(3):1131-42. doi: 10.2353/ajpath.2010.091143 PMID: 20651232
49. Sakamoto T, Kudoh T, Sakamoto K, Matsui K, Ogawa H. Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. Hypertens Res. 2014.